This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Study Of RoActemra/Actemra (Tocilizumab) in Toci...
Clinical trial

A Study Of RoActemra/Actemra (Tocilizumab) in Tocilizumab-Naive Patients With Rheumatoid Arthritis With Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) or Biologic Therapy

Read time: 1 mins
Last updated:29th Nov 2013
This two part, multi-center, open-label, single-arm study will evaluate the efficacy and safety of RoActemra/Actemra as a monotherapy or in combination with non-biologic disease modifying antirheumatic drugs (DMARDs) in patients with moderate to severe rheumatoid arthritis who have an inadequate response or are intolerant to non-biologic DMARDs or biologic therapy. 162 mg RoActemra/Actemra will be administered once a week by subcutaneous injection for up to 76 weeks.
Category Value
Study start date 2013-11-29

View full details